MetaStat, Inc. (MTST) 股价，以美元计价

MetaStat is a precision medicine company dedicated to transforming the treatment of patients with aggressive cancer. Our mission is to evolve cancer treatment into a manageable disease through targeted therapies that arrest cancer cell dissemination and metastatic progression. Aggressive cancer that spreads or metastasizes to other parts of the body is responsible for approximately 90% of cancer-related deaths, yet there are no anti-metastatic drugs on the market. MetaStat’s drug discovery program is focused on developing novel drug candidates that target the Mena-dependent metastatic cascade. MetaStat is developing novel small molecule and peptide-based kinase inhibitors that target the MAPKAPK2 pathway responsible for activation of Mena. The company’s Mena CDx companion diagnostic assay identifies patients with Mena-high tumors at risk for cancer metastasis and most likely to benefit from anti-Mena therapy. MetaStat is based in Boston, MA.